Keywords: valeant, sees, net, loss, climb, 2nd-qtr, usa

Valeant sees net loss climb 177% for 2nd-qtr

Article | 16 August 2004

Print This

The USA's Valeant Pharmaceuticals (formerly known as ICN) saw its netloss shoot up 177% to $41.3 million, or $0.49 per diluted share, as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in